Results 21 to 30 of about 70,790 (271)

Paradoxical worsening of nontuberculous mycobacterial disease after the discontinuation of antitumor necrosis factor therapy: A case report

Respiratory Medicine Case Reports, 2022
Antitumor necrosis factor–associated nontuberculous mycobacteria-immune reconstitution inflammatory syndrome (IRIS) has rarely been reported. An 84-year-old woman with a history of rheumatoid arthritis treated with etanercept was diagnosed with ...
Daijiro Nabeya, Tomoo Kishaba
doaj   +1 more source

Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta

Clinical pharmacology and therapy, 2020
Tumor necrosis factor (TNF) inhibitors are increasingly applied during pregnancy without clear knowledge of the impact on placenta and fetus. We assessed placental transfer and exposure to infliximab (n = 3) and etanercept (n = 3) in women with ...
Gaby A. M. Eliesen, J. van Drongelen, H. van Hove, Nina I. Kooijman, P. V. D. van den Broek, A. de Vries, N. Roeleveld, F. Russel, R. Greupink   +8 more
semanticscholar   +1 more source

Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis

Dermatology and Therapy, 2023
Introduction Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions with high morbidity and mortality and not clearly established treatment protocol.
Jiali Cao, Xuan Zhang, Xinzhu Xing, Jie Fan   +3 more
doaj   +1 more source

Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis

Mediators of Inflammation, 2013
It remains unclear whether etanercept penetrates directly into the contused brain and improves the outcomes of TBI by attenuating brain contents of TNF-α and/or stimulating newly formed neurogenesis.
Chong-Un Cheong, Ching-Ping Chang, Chien-Ming Chao, Bor-Chih Cheng, Chung-Zhing Yang, Chung-Ching Chio   +5 more
doaj   +1 more source

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

British Journal of Dermatology, 2017
GP2015 is a proposed etanercept biosimilar.
C. Griffiths, D. Thaçi, S. Gerdes, Petr Arenberger, G. Pulka, K. Kingo, J. Węgłowska, N. Hattebuhr, J. Poetzl, H. Woehling, G. Wuerth, M. Afonso   +11 more
semanticscholar   +1 more source

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Annals of the Rheumatic Diseases, 2018
Objectives Real-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid ...
B. Glintborg, A. Loft, E. Omerovic, O. Hendricks, A. Linauskas, J. Espesen, K. Danebod, D. Jensen, H. Nordin, E. B. Dalgaard, S. Chrysidis, S. Kristensen, J. Raun, H. Lindegaard, N. Manilo, S. H. Jakobsen, I. Hansen, Dorte Dalsgaard Pedersen, I. Sørensen, L. Andersen, J. Grydehøj, F. Mehnert, N. Krogh, M. Hetland   +23 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial

Pediatrics, 2019
Etanercept in a randomized clinical trial exhibited potential benefit as an adjunctive IVIg treatment of acute KD in select prespecified subgroups. BrightcoveDefaultPlayer10.1542/6138644048001PEDS-VA_2018-3675 Video Abstract OBJECTIVES: Patients with ...
M. Portman, N. Dahdah, A. Slee, A. Olson, N. Choueiter, B. Soriano, S. Buddhe, C. Altman   +7 more
semanticscholar   +1 more source

A case of postoperative nasopharyngeal reflux associated with retropharyngeal lymphangioma in newborn infant [PDF]

Korean Journal of Pediatrics, 2010
Tumor necrosis factor-?#6184;TNF-?#6752;is a major proinflammatory cytokine involved in the pathophysiology of juvenile rheumatoid arthritis. Etanercept is an effective inhibitor of TNF-?#6177;nd has shown a beneficial effect in patients with JRA ...
Ah Reum Kwon, Eun Jung Park, Ki Hwan Kim, Dong Soo Kim   +3 more
doaj   +1 more source

TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats

BMC Neuroscience, 2019
Background Systemic inflammation is an important risk factor for neurodevelopmental impairments in preterm infants. Premyelinating oligodendrocytes are main building blocks of white matter in preterm infants and vulnerable to oxidative stress and ...
Seung Han Shin, Ee-Kyung Kim, Kyung-yup Lee, Han-Suk Kim   +3 more
doaj   +1 more source